Lundbeck partners with Nanomerics for drug delivery collaboration

30 April 2014

UK-based drug delivery company Nanomerics, a spin out of the University College London, has announced a collaborative research project with UCL, Exeter University and the Danish CNS specialist Lundbeck (LUND: CO) to develop drug delivery methods to the brain.

Through the collaboration, Nanomerics aims to develop new ways to deliver antibodies to the brain, building on the molecular envelope technology it has developed. The consortium aims to develop antibody medicines that are active in the brain for the treatment of conditions such as dementia and brain cancer. UCL will lead research, backed with just over £1 million ($1.6 million) in funding from the Engineering and Physical Sciences Research Council’s (EPSRC) Health Impact Partnerships award scheme.

Targeting brain tumors

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK